The FDA moved to stabilize leadership across its drug and biologics review centers, with Michael Davis and Karim Mikhail promoted from acting to permanent directors. The shift comes as the agency awaits confirmation of the next commissioner, signaling a return to “continuity and stability” after a period of turnover. Alongside these appointments, HHS also created a new deputy commissioner role focused on technology and artificial intelligence, reflecting an institutional push to integrate advanced tools into regulatory operations. Executives and investors will be watching how quickly the new structure translates into consistent decision-making across CDER and CBER.